Benefits
Everyday digestive comfort
In a randomized clinical study, the probiotic amylase blend reduced everyday gastrointestinal symptoms versus placebo, including measures of bloating and abdominal discomfort. Changes in regularity, flatulence, and constipation were smaller and did not reach statistical significance versus placebo.
Bacteria-and-fungi (mycobiome) balance
Most probiotics ignore the fungal side of the gut. Mycohsa is built to support a healthy balance of both bacteria and yeasts. Human microbiome studies found that taking the blend shifted the gut community toward a more favorable bacterial and fungal profile.
Supports healthy Candida levels
By combining the beneficial yeast Saccharomyces boulardii with biofilm-digesting amylase, the blend is designed to discourage overgrowth of Candida and other opportunistic yeasts. This effect has been shown only in laboratory (in-vitro biofilm) studies and has not been demonstrated as a human outcome.
Immune support
A large share of immune tissue lines the gut, so a balanced microbiome supports immune readiness. By helping maintain healthy bacterial and fungal communities and a strong gut barrier, the blend supports normal immune function.
Mechanism of action
Amylase digests the biofilm matrix
Pathogenic bacteria and fungi cooperate to build polymicrobial biofilms held together by a polysaccharide matrix. The amylase enzymatically degrades these sugars, helping break down the "digestive plaque" so probiotics can reach and recolonize the gut lining.
Dual bacterial and fungal targeting
BIOHM's founding research showed gut dysbiosis often involves fungi such as Candida albicans partnering with bacteria like E. coli and Serratia marcescens. The blend pairs bacterial strains with a beneficial yeast to address both kingdoms of the microbiome rather than bacteria alone.
Saccharomyces boulardii
S. boulardii is a non-colonizing probiotic yeast that competes with pathogenic yeasts, supports the gut barrier, and is naturally resistant to antibiotics, helping maintain balance during and after a course of antibiotics.
Short-chain fatty acid production
The Lactobacillus and Bifidobacterium strains ferment fiber into short-chain fatty acids such as butyrate, which nourish colon cells, reinforce the gut barrier, and help maintain an environment that crowds out opportunistic microbes.
Clinical trials
Randomized controlled clinical study of the probiotic amylase blend (Mycohsa / BIOHM) on everyday gastrointestinal symptoms. (La Monica et al. 2023, Beneficial Microbes)
Adults with gastrointestinal symptoms.
The blend significantly reduced gastrointestinal symptoms versus placebo, including measures of bloating and abdominal discomfort, supporting its use for everyday digestive comfort.
Randomized, placebo-controlled, double-blind study of the probiotic amylase blend on gut microbiota composition. (Ghannoum et al. 2024, Life)
Healthy adults, randomized and placebo-controlled.
The blend positively modulated the gut microbiota versus placebo, favorably shifting bacterial and fungal populations and reinforcing the rationale for its dual bacteria-and-fungi approach.
Human study evaluating gut microbiome changes after daily consumption of the BIOHM probiotic blend. (Ghannoum et al. 2021, Current Issues in Molecular Biology)
Healthy adults.
Consuming the blend altered the gut microbiome, increasing beneficial bacteria and shifting the bacterial and fungal communities toward a more balanced, favorable profile.
Laboratory study testing the probiotic combination (Lactobacillus, Bifidobacterium, S. boulardii) plus amylase against polymicrobial biofilms formed by Candida albicans with bacteria. (Hager et al. 2019, mBio)
In vitro polymicrobial biofilm models.
The probiotic-plus-amylase combination significantly reduced the thickness and biomass of bacterial-fungal biofilms and lowered pro-inflammatory markers, providing the mechanistic basis for the blend's biofilm-disruption approach.